- DKK155.51bn
- DKK180.62bn
- $3.72bn
Brief: Genmab Says Phase 1/2 Rainfol-01 Data Show Rina-S And Bevacizumab Combination Tolerable
Brief: Genmab Says Orbis Controls 4.99% Of Genmab A/S Voting Rights As Of March 27
Brief: Genmab Completed Share Buy-Back Program On March 13
Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board (updated)
Genmab slides as 'disappointing' 2026 outlook outweighs Q4 results
Brief: Genmab FY Oper Profit Up At $1,065 Mln
Brief: Genmab Announces Initiation of Share Buy-Back Program
Brief: Genmab Outlook FY Revenue USD 4,065-4,395 Million
Jefferies resumes Genmab at 'buy' on a 'catalyst-rich 2026'
Europe Research Roundup: Allianz, Koninklijke Philips, St. James's Place
Focus: Drugmakers turn to AI to speed trials, regulatory submissions
Brief: Genmab Says Net Sales Of Darzalex In 2025 $14,351 Mln
Genmab shares fall after cancer drug trial failed to meet endpoint
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study (updated)
NASDAQ RESUMED AT 01:50 PM
Brief: Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance
Genmab's blood cancer drug fails main goal in late-stage study
NASDAQ TRADE HALT HALT NEWS PENDING AT 12:55 PM
Brief: Genmab Partners With Anthropic To Accelerate Research And Development Through Agentic AI